These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 14699463)

  • 1. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial.
    MacArthur RD; Miller M; Albertson T; Panacek E; Johnson D; Teoh L; Barchuk W
    Clin Infect Dis; 2004 Jan; 38(2):284-8. PubMed ID: 14699463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [C-reactive protein concentrations during initial (empiric) treatment of neonatal sepsis].
    Janković B; Pasić S; Marković M; Veljković D; Milicić M
    Srp Arh Celok Lek; 2001; 129 Suppl 1():17-22. PubMed ID: 15637985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy.
    Degoricija V; Sharma M; Legac A; Gradiser M; Sefer S; Vucicević Z
    Croat Med J; 2006 Jun; 47(3):385-97. PubMed ID: 16758516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial.
    Orozco H; Arch J; Medina-Franco H; Pantoja JP; González QH; Vilatoba M; Hinojosa C; Vargas-Vorackova F; Sifuentes-Osornio J
    Arch Surg; 2006 Feb; 141(2):150-3; discussion 154. PubMed ID: 16490891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.
    Gaieski DF; Mikkelsen ME; Band RA; Pines JM; Massone R; Furia FF; Shofer FS; Goyal M
    Crit Care Med; 2010 Apr; 38(4):1045-53. PubMed ID: 20048677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sepsis and septic shock: selection of empiric antimicrobial therapy.
    Cunha BA
    Crit Care Clin; 2008 Apr; 24(2):313-34, ix. PubMed ID: 18361948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock.
    Pontes-Arruda A; Aragão AM; Albuquerque JD
    Crit Care Med; 2006 Sep; 34(9):2325-33. PubMed ID: 16850002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sepsis in the critically-ill patient].
    Christensen VB; Nielsen JS; Tønnesen EK
    Ugeskr Laeger; 2007 Feb; 169(8):703-5. PubMed ID: 17313921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an antibiotic algorithm on the adequacy of empiric antibiotic therapy given by a medical emergency team.
    Miano TA; Powell E; Schweickert WD; Morgan S; Binkley S; Sarani B
    J Crit Care; 2012 Feb; 27(1):45-50. PubMed ID: 21798704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.
    Oliveira CF; Nogueira de Sá FR; Oliveira DS; Gottschald AF; Moura JD; Shibata AR; Troster EJ; Vaz FA; Carcillo JA
    Pediatr Emerg Care; 2008 Dec; 24(12):810-5. PubMed ID: 19050666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
    Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
    Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current management of septic shock.
    Russel JA
    Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome.
    Leone M; Bourgoin A; Cambon S; Dubuc M; Albanèse J; Martin C
    Crit Care Med; 2003 Feb; 31(2):462-7. PubMed ID: 12576952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality.
    Nguyen HB; Corbett SW; Steele R; Banta J; Clark RT; Hayes SR; Edwards J; Cho TW; Wittlake WA
    Crit Care Med; 2007 Apr; 35(4):1105-12. PubMed ID: 17334251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial.
    Eid A; Wiedermann CJ; Kinasewitz GT
    Anesth Analg; 2008 Nov; 107(5):1633-8. PubMed ID: 18931224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing antimicrobial therapy in sepsis and septic shock.
    Kumar A
    Crit Care Clin; 2009 Oct; 25(4):733-51, viii. PubMed ID: 19892250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study.
    Oppert M; Engel C; Brunkhorst FM; Bogatsch H; Reinhart K; Frei U; Eckardt KU; Loeffler M; John S;
    Nephrol Dial Transplant; 2008 Mar; 23(3):904-9. PubMed ID: 18065435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J;
    Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
    Buda S; Riefolo A; Biscione R; Goretti E; Cattabriga I; Grillone G; Bacchi-Reggiani L; Pacini D
    J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):440-5. PubMed ID: 16085247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial.
    Hentrich M; Fehnle K; Ostermann H; Kienast J; Cornely O; Salat C; Ubelacker R; Buchheidt D; Behre G; Hiddemann W; Schiel X
    Crit Care Med; 2006 May; 34(5):1319-25. PubMed ID: 16540956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.